Nuritas will exhibit at Vitafoods Europe 2026, taking place 5–7 May at Fira Barcelona Gran Via, at Stand 5D30. The company has launched a double-blinded randomized controlled trial (NCT07528469), in collaboration with Liverpool John Moores University and StudySetGo, assessing 2.4 g PeptiStrong plus 10 g whey protein versus 20 g whey alone in healthy adults aged 60 to 85.
The 30-day study plans to enroll 80 participants, with grip strength as the primary endpoint and secondary measures including gait speed, chair stand performance, balance, body composition, quality of life, fatigue and inflammatory markers; results are expected in Q3 2026.
Nuritas is also expanding European distribution through new partnerships with Alifarma for Spain and Portugal, Faravelli for Italy, and Vivatis Pharma for Poland, the Czech Republic, Slovakia and the Baltic states.
The company notes more than 100 formulations worldwide that feature its ingredients. Nuritas uses AI to discover bioactive peptides; it claims that PeptiStrong is a fava bean-derived peptide supported by three clinical studies for muscle strength, energy and exercise recovery.
